Enrolment completed and recommended phase II dose reached for OXC-101

Oxcia AB, today announced that it has completed enrollment and evaluation of the last patient in the MASTIFF Phase I clinical trial of OXC-101 in escalating doses for the treatment of patients with advanced solid malignant tumours. The recommended phase II dose has now been determined.  Study results will be reported the coming months.

“Completing enrolment in the MASTIFF study and determining the Phase 2 Recommended Dose are very significant milestone for our company and allows us to finalize planning of our phase II study” said Austin Smith, M.D, Chief Medical Officer, Oxcia. “We truly appreciate the participation of patients and the support we have received from investigators who believe that OXC-101 has the potential to meet the clinical need for a new safe and effective therapy for patients with difficult to treat cancers”.

Recruitment in the phase I study for advanced hematological cancers, MAATEO, is still ongoing.

Briefly about OXC-101

With its unique dual mechanism of action, OXC-101 takes advantage of the high endogenous oxidative stress and oxidative DNA damage in cancer cells by disrupting the cell-division complex microtubule and inhibiting the repair enzyme MTH1. OXC-101 stops the cancer cell from dividing, causes more oxidative stress and oxidative DNA damage which the cancer cell cannot handle, and the cell dies. Healthy cells are only marginally affected, which lays the foundation for OXC-101 good tolerability. It is also orally available.

For further information please contact:

Austin Smith, CMO

Email: austin.smith@oxcia.com

Or:

Ulrika Warpman Berglund, CEO

Phone: +46 (0) 73 270 96 05

Email: ulrika.warpmanberglund@oxcia.com

Briefly about Oxcia

Oxcia AB is a pioneer in oxidative DNA damage and DNA Damage Response (DDR - the processes the body uses to repair the damage that occurs to DNA) with a focus on developing new safe treatments for patients suffering from diseases caused by cancer or inflammation. Oxcia currently has two DDR drug candidates, both with the potential to become first-in-class drugs. OXC-101 (Karonudib, TH1579) is being investigated in two ongoing clinical phase 1 studies, one in advanced solid tumors and one in hematological cancers. OXC-201 (TH5487) is developed against inflammatory and fibrosis-related diseases, such as pulmonary fibrosis, and is in the preclinical phase.

More information about Oxcia is available at www.oxcia.com